After ‘tremendous’ FY 2021, Prescient Therapeutics well-funded to advance cancer-fighting therapies
Clinical-stage oncology company Prescient Therapeutics’ (ASX: PTX) strong cash position will enable it to advance its multiple...
Clinical-stage oncology company Prescient Therapeutics’ (ASX: PTX) strong cash position will enable it to advance its multiple...
Biotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pipeline...
Prescient Therapeutics (ASX: PTX) has moved closer to developing its unique CAR-T cancer technology after revealing...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has revealed two of its assets have been selected...
Biotech company Prescient Therapeutics (ASX: PTX) emerged from a trading halt this morning to unveil two significant...
Cancer drug developer Prescient Therapeutics (ASX: PTX) is expanding its Phase 1b study in patients with acute...
Oncology company Prescient Therapeutics (ASX: PTX) has unveiled a potentially lucrative collaboration with Adelaide-based Carina Biotech to...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.